Search

Displaying results 5421 - 5430 of 9132 in total
  1. Drug

    Demexiptiline

    go.drugbank.com/drugs/DB08998
    Experimental

    It is a tricyclic antidepressant which acts primarily as a norepinephrine reuptake inhibitor.

  2. Drug

    Prifinium

    go.drugbank.com/drugs/DB13254
    Experimental

    Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome [A175027].

  3. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

  4. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. … Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders.

  5. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  6. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  7. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth.

  8. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  9. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  10. Drug

    Risuteganib

    go.drugbank.com/drugs/DB14911
    Investigational

    Risuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema).